References
- Nemtsas P, Arnaoutoglou M, Perifanis V, et al. Neurological complications of β-thalassemia. Ann Hematol. 2015;94(8):1261–1265.
- Papanastasiou DA, Papanicolaou D, Magiakou AM, et al. Peripheral neuropathy in patients with β-thalassaemia. J Neurol Neurosurg Psychiatry. 1991;54(11):997–1000.
- Sawaya RA, Zahed L, Taher A. Peripheral neuropathy in thalassaemia. Ann Saudi Med. 2006;26(5):358–363.
- Stamboulis E, Vlachou N, Drossou-Servou M, et al. Axonal sensorimotor neuropathy in patients with β-thalassaemia. J Neurol Neurosurg Psychiatry. 2004;75(10):1483–1486.
- Wong V, Li A, Lee AC. Neurophysiologic study of β-thalassemia patients. J Child Neurol. 1993;8(4):330–335.
- Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314(14):869–873.
- Orton RB, de Veber LL, Sulh HM. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol. 1985;20(4):153–156.
- Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458–465.
- Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology. 1999;53(8):1660–1664.
- Zafeiriou DI, Kousi AA, Tsantali CT, et al. Neurophysiologic evaluation of long-term desferrioxamine therapy in β-thalassemia patients. Pediatr Neurol. 1998:18(5):420–424.
- Kardelen F, Tezcan G, Akcurin G, et al. Heart rate variability in patients with thalassemia major. Pediatr Cardiol. 2008:29(5):935–939.
- Teunissen LL, Notermans NC, Wokke JH. Relationship between ischemia and neuropathy. Eur Neurol. 2000:44(1):1–7.
- Bertfield DL, Jumma O, Pitceathly RD, et al. Copper deficiency: an unusual case of myelopathy with neuropathy. Ann Clin Biochem. 2008;45(Pt 4):434–435.